Study 4 of 57Semaglutide literatureSemanticScholar2010
Semantic Scholar search for Semaglutide
Not reported in abstract.
Where it sits
this study against the rest of the semaglutide corpus13
Preclinical · this one
34
Observational
2
Open-label
2
Randomised
6
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2010
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Elsewhere in the Semaglutide corpus
DSemaglutide and Suicidality in Adults with Overweight or Obesity: A Bayesian Meta-Analysis of Randomized Trialsbiorxiv-preprint · Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.reviewBWeight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort studybiorxiv-preprint · At 16 weeks, NMGP users lost 8.3% of their baseline weight.HumanBSide effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective studybiorxiv-preprint · 34% lower relative odds of reporting GI side effects by week 16, p=0.001, n=2,481 per group.HumanBA study on risk factors for the progression from T2DM to end-stage renal disease based on Mendelian randomization and logistic regression analysis.Renal failure · 2026 · n=875 · AUC of the logistic regression-based nomogram was 0.88 (95% CI: 0.85-0.91).HumanBFeasibility and acceptability of an everyday patient-centered discussion model for primary care: An exploratory, single-center study in the VA primary care setting.PEC innovation · 2026 · n=23 · Mean SDM-Q-9 score was 90.9 out of 100.HumanBOral Health Outcomes with GLP1 Receptor Agonists Compared with Other Metabolic Interventionsbiorxiv-preprint · 2026 · 8.69% of GLP-1 users developed at least one newly documented oral-health condition.Human